                  NON-DISCLOSURE AGREEMENT


This Non-Disclosure Agreement (the "Agreement") is entered into as of 
the 22nd day of April, 2024 (the "Effective Date"), by and between:

     BioTech Innovations, a Delaware corporation with its principal place 
     of business at 200 Research Park Drive, San Diego, CA 92121 
     (hereinafter referred to as "Disclosing Party"),

and

     PharmaCorp, a Delaware corporation with its principal place of 
     business at 1000 Pharmaceutical Plaza, New York, NY 10019 
     (hereinafter referred to as "Receiving Party").


                              RECITALS

WHEREAS, Disclosing Party possesses certain proprietary and confidential 
information relating to its biotechnology research, development projects, 
and business operations; and

WHEREAS, Receiving Party desires to receive and evaluate such confidential 
information for the purpose of exploring a potential business relationship 
between the parties (the "Purpose"); and

WHEREAS, Disclosing Party is willing to disclose such confidential 
information to Receiving Party subject to the terms and conditions set 
forth herein.

NOW, THEREFORE, in consideration of the mutual promises and covenants 
contained herein, the parties agree as follows:


1. DEFINITION OF CONFIDENTIAL INFORMATION

   1.1 "Confidential Information" means any and all information, data, 
       materials, documents, or knowledge, whether written, oral, 
       electronic, visual, or in any other form, disclosed by Disclosing 
       Party to Receiving Party, including but not limited to:

       (a) Scientific, technical, and research information, including 
           research protocols, methodologies, experimental data, test 
           results, formulas, compounds, compositions, processes, 
           procedures, techniques, know-how, and discoveries;

       (b) Product information, including product specifications, designs, 
           plans, prototypes, samples, models, and manufacturing 
           processes;

       (c) Business information, including business plans, strategies, 
           financial information, pricing, cost data, sales data, customer 
           lists, supplier lists, marketing plans, and forecasts;

       (d) Intellectual property, including patents, patent applications, 
           inventions, trade secrets, copyrights, trademarks, and 
           proprietary rights;

       (e) Personnel information, including employee lists, compensation 
           information, and organizational structures;

       (f) Any other information that Disclosing Party designates as 
           confidential or that, given the nature of the information or 
           circumstances surrounding disclosure, reasonably should be 
           understood to be confidential;

       (g) All analyses, compilations, studies, reports, summaries, or 
           other materials prepared by Receiving Party that contain, 
           reflect, or are based upon any of the foregoing.


2. CONFIDENTIALITY OBLIGATIONS

   2.1 Protection of Confidential Information. Receiving Party agrees to 
       hold all Confidential Information in strict confidence and to use 
       reasonable efforts to protect such Confidential Information from 
       unauthorized disclosure or use.

   2.2 Permitted Use. Receiving Party may use Confidential Information 
       solely for the Purpose and for no other purpose whatsoever without 
       the prior written consent of Disclosing Party.

   2.3 Disclosure Limitations. Receiving Party shall not disclose any 
       Confidential Information to any third party, except that Receiving 
       Party may disclose Confidential Information to its employees, 
       affiliates, consultants, advisors, and representatives who have a 
       legitimate need to know such information for the Purpose and who 
       are bound by confidentiality obligations.

   2.4 Standard of Care. Receiving Party shall exercise at least the same 
       degree of care in protecting Confidential Information as it 
       exercises in protecting its own confidential information, but in no 
       event less than reasonable care.


3. EXCEPTIONS

   3.1 The obligations set forth in Section 2 shall not apply to any 
       Confidential Information that:

       (a) Was known to Receiving Party prior to disclosure by Disclosing 
           Party, as evidenced by written records;

       (b) Is or becomes publicly available through no breach of this 
           Agreement by Receiving Party;

       (c) Is rightfully received by Receiving Party from a third party 
           without breach of any confidentiality obligation;

       (d) Is independently developed by Receiving Party without use of or 
           reference to Confidential Information, as evidenced by written 
           records;

       (e) Is required to be disclosed by law, regulation, court order, or 
           other legal process, provided that Receiving Party provides 
           Disclosing Party with prompt written notice of such requirement 
           to permit Disclosing Party to seek a protective order or other 
           appropriate remedy.


4. TERM

   4.1 This Agreement shall commence on the Effective Date and shall 
       continue for a period of twelve (12) months, unless earlier 
       terminated by either party upon thirty (30) days' written notice to 
       the other party.

   4.2 The confidentiality obligations set forth in Section 2 shall 
       survive termination of this Agreement for a period of one (1) year 
       from the date of termination.


5. NO LICENSE OR TRANSFER OF RIGHTS

   5.1 Nothing in this Agreement grants to Receiving Party any license, 
       right, title, or interest in or to any Confidential Information, 
       patents, copyrights, trademarks, trade secrets, or other 
       intellectual property rights of Disclosing Party.

   5.2 All Confidential Information remains the sole property of 
       Disclosing Party.


6. NO WARRANTY

   6.1 ALL CONFIDENTIAL INFORMATION IS PROVIDED "AS IS" WITHOUT ANY 
       WARRANTY OF ANY KIND, EXPRESS OR IMPLIED. DISCLOSING PARTY MAKES 
       NO REPRESENTATION OR WARRANTY REGARDING THE ACCURACY, COMPLETENESS, 
       OR UTILITY OF ANY CONFIDENTIAL INFORMATION.


7. REMEDIES

   7.1 Receiving Party acknowledges that any unauthorized disclosure or 
       use of Confidential Information may cause irreparable harm and 
       significant injury to Disclosing Party, the extent of which may be 
       difficult to ascertain. Accordingly, Receiving Party agrees that 
       Disclosing Party shall have the right to seek immediate injunctive 
       relief and other equitable remedies to prevent or restrain any 
       breach or threatened breach of this Agreement, in addition to any 
       other rights and remedies available at law or in equity.

   7.2 Receiving Party shall be liable for any breach of this Agreement by 
       its employees, affiliates, consultants, advisors, or 
       representatives.


8. GENERAL PROVISIONS

   8.1 Entire Agreement. This Agreement constitutes the entire agreement 
       between the parties regarding the subject matter hereof and 
       supersedes all prior agreements, understandings, and communications, 
       whether written or oral.

   8.2 Amendments. No amendment or modification of this Agreement shall be 
       effective unless in writing and signed by both parties.

   8.3 Waiver. No waiver of any provision of this Agreement shall be 
       effective unless in writing and signed by the party against whom 
       such waiver is sought to be enforced. No waiver shall constitute a 
       waiver of any other provision or of the same provision on another 
       occasion.

   8.4 Severability. If any provision of this Agreement is held to be 
       invalid or unenforceable, the remaining provisions shall remain in 
       full force and effect.

   8.5 Assignment. Receiving Party may not assign this Agreement without 
       the prior written consent of Disclosing Party. This Agreement shall 
       be binding upon and inure to the benefit of the parties and their 
       respective successors and permitted assigns.

   8.6 Notices. All notices under this Agreement shall be in writing and 
       shall be deemed delivered when delivered personally, sent by 
       confirmed facsimile or electronic mail, or three (3) business days 
       after being sent by certified mail, return receipt requested.

   8.7 Counterparts. This Agreement may be executed in counterparts, each 
       of which shall be deemed an original and all of which together 
       shall constitute one and the same instrument.

   8.8 Independent Contractors. Nothing in this Agreement creates any 
       partnership, joint venture, agency, or employment relationship 
       between the parties.


IN WITNESS WHEREOF, the parties have executed this Agreement as of the 
date first written above.


BIOTECH INNOVATIONS


By: _________________________________

Name: _________________________________

Title: _________________________________

Date: _________________________________



PHARMACORP


By: _________________________________

Name: _________________________________

Title: _________________________________

Date: _________________________________
